CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH

本分项目是CTSA供资的估计百分比，即 被用于广泛的研究领域(艾滋病研究、儿科研究或 临床试验)。列出的总成本仅是对CTSA金额的估计 用于这一研究领域的基础设施，而不是由 授予子项目或子项目工作人员的NCRR补助金。 我们已经建立了马萨诸塞大学临床与转化科学中心(UMCCTS)，其中包括五个麻省理工大学校区。在运作上，该中心位于大学伍斯特校区，由医学院管理。该中心是马萨诸塞州大学所有校区临床和转化型科学家的“学术之家”。CTSA计划将在世界级基础科学的基础上进行临床和转化研究，2006年将诺贝尔生理学或医学奖授予克雷格·梅洛，2008年将阿尔伯特·拉斯克奖授予维克托·安布罗斯就是明证。UMCCTS的目标是：1)通过招募优秀的T1研究领导者，建立创新的研究核心设施，并基于UMASS的发现开发新的疗法、设备和干预措施，加速早期转化型(TL)研究；2)整合新英格兰中部和马萨诸塞州独特的临床研究和医疗保健提供网络，通过招聘优秀的T2和T3研究领导者，并通过开发创新的T2/T3核心设施，建立和扩大T2(临床有效性研究)和T3(实施和传播研究)的能力；以及加强患者和社区的推广，并参与临床/基于人群的研究；3)UMCCTS将与UMAS系统的所有校园和学校合作，开发促进临床和翻译研究事业的计划、课程和教师支持系统。州长德瓦尔·帕特里克和马萨诸塞州立法机构最近制定了一项立法，承诺将10亿美元的州投资直接用于英联邦的生命科学。凭借9000万美元的种子资金，该大学建立了UMASS高级治疗集群(UMATC)，其中包括RNA治疗研究所、干细胞生物学和再生医学中心以及基因治疗中心。UMATC加入了马萨诸塞州生物实验室、迈耶斯初级保健研究所和联邦医学这四个在学术中心很少找到的创新组成部分，加快了临床和转化研究中从工作台到床边到社区的发现。相关性(参见说明)：马萨诸塞大学临床与转化科学中心(UMCCTS)将通过为所有大学临床研究人员提供“学术之家”来改变临床和转化研究的进行方式。UMCCTS将提供强有力的试点资助计划、全面的教育和职业发展计划以及创新的核心设施，以支持和培养临床研究人员。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. We have established the University of Massachusetts Center for Clinical and Translational Science (UMCCTS) which includes the five UMass campuses. Operationally, the Center is located at the University's Worcester campus and managed by the School of Medicine. The Center serves as the "academic home" for clinical and translational scientists across all UMass campuses. The CTSA program will build clinical and translational research upon a foundation of world class basic science as evidenced by the award of the Nobel Prize in Physiology or Medicine to Craig Mello in 2006 and the Albert Lasker Award to Victor Ambros in 2008. The UMCCTS aims are to: 1) Accelerate early phase translational (Tl) studies by recruiting outstanding T1 research leaders; establishing innovative research core facilities; and developing new therapies, devices, and interventions based upon UMass discoveries; 2) Integrate unique networks of clinical research and healthcare delivery in Central New England and Massachusetts at-large to build and expand T2 (clinical effectiveness research) and T3 (implementation and dissemination research) capacity by recruiting outstanding T2 and T3 research leaders, and by developing innovative T2/T3 core facilities; and enhancing patient and community outreach and participation in clinical/population-based research; 3) The UMCCTS will work collaboratively with all campuses and schools ofthe UMass system in developing programs, curricula, and faculty support systems that promote careers in clinical and translational research. Governor Deval Patrick and the Massachusetts Legislature recently enacted legislation committing $1 billion in state investment to be directed to the Life Sciences in the Commonwealth. With $90 million in seed funding, the University has established the UMass Advanced Therapeutics Cluster (UMATC) which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. The UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute, and Commonwealth Medicine, four innovative components that are rarely found in academic centers, to speed bench to bedside to community discoveries in clinical and translational research. RELEVANCE (See instructions): The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will transform the conduct of clinical and translational research by providing an "academic home" for all university clinical investigators. The UMCCTS will provide robust pilot grant programs, comprehensive education and career development programs, and innovative core facilities to support and nurture clinical investigators.